DKI Combined With APT for Post-treatment Assessment of Ovarian Malignancies and Correlation With XRCC2 Gene

Launched by QIANQIAN QU · Nov 30, 2022

Keywords

ClinConnect Summary

This clinical trial is studying new imaging techniques called DKI and APT to help assess how well treatment is working for women with ovarian cancer. Ovarian cancer is a serious condition, and doctors are looking for better ways to monitor its progress after treatment. The trial aims to see if these non-invasive imaging methods can provide valuable information about changes in the tumor, especially in relation to a specific gene called XRCC2, which may influence treatment outcomes.

To participate in this trial, women aged 14 to 25 who have never had ovarian tumors or surgery and are currently receiving a specific type of chemotherapy may be eligible. Participants will undergo DKI and APT imaging, as well as tests related to the XRCC2 gene, both before and after their treatment. This research could help doctors personalize treatment plans for ovarian cancer patients and ultimately improve their chances of recovery. The trial is not yet recruiting participants, so those interested will need to wait for further announcements.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • No previous history of ovarian tumours or ovarian surgery; no concurrent other tumours, no history of oncology or treatment such as radiotherapy or chemotherapy; confirmed by pathological histology; receiving chemotherapy with a combination of platinum and purple shirt for at least 3 cycles; no contraindications to MRI
• Exclusion Criteria:
• • Recurrent ovarian malignancy; too old, poor physical infrastructure; severe medical comorbidity; incomplete patient data collection; lost to follow-up